NATCO PHARMA
|
|
| BOM : 524816 NSE : NATCOPHARM | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
May 27,2022 |
|
Price(EOD): ₹ 679.90
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 12,414.97 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NATCO PHARMA | -3.6% | -13.4% | -35.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.9% | -0.2% | 29.4% |
| DIVIS LABORATORIES | -9.8% | -22.2% | -15.5% |
| DR REDDYS LABORATORIES | 2.8% | 7.7% | -17.4% |
| CIPLA | -0.4% | -1.1% | 3.1% |
| GLAND PHARMA | -2.5% | -7.7% | -13% |
| PIRAMAL ENTERPRISES | -12.8% | -23.8% | 9.1% |
| CADILA HEALTHCARE | 3.1% | 8.4% | -40.1% |
| TORRENT PHARMACEUTICALS | 12.4% | 8.5% | 6.5% |
FUNDAMENTAL ANALYSIS OF NATCO PHARMA
[ Q(TTM): Dec2021, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NATCO PHARMA
[As on : May 27,2022
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
28.14
P/E Calculated based on EPS of 24.16
[ Mar2021 - Consolidated Results ] 3.02
P/B Calculated based on Book Value of 224.88
[ Mar2021 - Consolidated Results ] 7.39
P/S Calculated based on Revenues of 1679.3 Cr
[ TTM - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
114% 189% 290% |
SHARE PRICE MOMENTUM OF NATCO PHARMA
NATCO PHARMA vs SENSEX
DEBT OF NATCO PHARMA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2021 2020 2019 Avg_3yrs |
0.06 0.08 0.11 0.08 |
0.07 0.08 0.11 0.09 |
|
[Last Annual Data : Mar2021]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF NATCO PHARMA
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2022 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF NATCO PHARMA
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
48.59% 44.4% 30.37% 23.5% |
57.8% 23.39% 13.61% 26.81% |
| QtrlyTrend |
8 | |
| Latest Qtr: Dec2021 | ||
| Quarterly Result Analysis → | ||
NATCO PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE LARGE MIDCAP | 0.2% | -6.3% | 7.1% |
| S&P BSE 200 | 0.2% | -6.3% | 7.2% |
| S&P BSE 250 LARGEMIDCAP | 0.1% | -6.4% | 7.2% |
| S&P BSE MID CAP | 0.1% | -8.6% | 3.9% |
| S&P BSE 500 | -0.1% | -6.8% | 7.2% |
| S&P BSE ALLCAP | -0.3% | -7.1% | 7.5% |
| S&P BSE 150 MIDCAP | -0.5% | -8% | 7.7% |
| S&P BSE 400 MIDSMALLCAP | -1.3% | -9.3% | 7.2% |
| S&P BSE MIDSMALLCAP | -1.5% | -10.1% | 7.1% |
| S&P BSE HEALTHCARE | -2% | -8.1% | -8.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | -0.2% | -6.9% | 7% |
| NIFTY LARGE MIDCAP 250 | -0.3% | -7.2% | 7.4% |
| NIFTY500 MULTICAP 50:25:25 | -0.8% | -8.3% | 7.2% |
| NIFTY MIDCAP150 | -0.9% | -8.3% | 7.8% |
| NIFTY MID SMALL400 | -1.5% | -9.7% | 7.3% |
| NIFTY PHARMA | -3% | -5.8% | -9.7% |
You may also like the below Video Courses
FAQ about NATCO PHARMA
Is NATCO PHARMA good for long term investment?
As on May 27,2022, the Fundamentals of NATCO PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of NATCO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NATCO PHARMA UnderValued or OverValued?
As on May 27,2022, NATCO PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NATCO PHARMA ?
As on May 27,2022, the Intrinsic Value of NATCO PHARMA is Rs. 235.29 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 318.10
Fair Value [Median EV / Sales Model] : Rs. 235.29
Fair Value [Median Price / Sales Model] : Rs. 174.19
Median Fair Value of NATCO PHARMA : Rs. 235.29
Is NATCO PHARMA trading at a Premium or Discount?
As on May 27,2022, NATCO PHARMA is trading at a Premium of 189% based on the estimates of Median Intrinsic Value!
Check out Annual Financials of Industry Peers
Check out Quarterly Results of Industry Peers
Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].
